Osteoarthritis & Cartilage – Intricacies of Imaging in Clinical Trials
Join Dr. Olga Kubassova, CEO and Prof. Mikael Boesen, Head of Musculoskeletal Imaging Research during a live webinar to discuss optimal use of imaging to empower clinical development of novel therapeutics in osteoarthritis and cartilage repair.
If you are interested in receiving a replay link, please email email@example.com
About the Webinar:
A rising need for effective treatment that can both reduce pain and positively impact cartilage repair makes drug developers innovate in trial designs and use more informative biomarkers, including imaging.
Key discussion points:
- Patient selection and appropriate use of imaging to account for comorbidities
- FDA approved imaging endpoints for disease modification claims and use of AI in increasing their sensitivity
- Novel imaging and scoring for osteoarthritis and cartilage repair clinical trials
About Dr. Olga Kubassova:
Mathematician and computer scientist with 10+ years expertise in actively managing innovation in life science companies. Scientific interests are in quantitative imaging, development of novel efficacy methodologies, AI, Machine Learning in clinical trials.
About Prof. Mikael Boesen:
Prof. of musculoskeletal imaging, hands-on radiologist with 20 years of international experience in clinical research in inflammatory and degenerative joint diseases. Dr. Boesen is a global PI, speakers and author of 80+ articles and book chapters. He brings together cross-therapeutic area expertise and helps drug developers to think outside the box when it comes to designing clinical trials and selection imaging strategy.
IAG is a strategic partner to bio-pharmaceutical companies developing new treatments to improve patients’ lives. Our dynamic Strategy, Trial Solutions and Bio-Partnering divisions work closely to meet critical needs of biotechnology companies: funding, clinical development and monetization of their assets. We fuse decades of therapeutic insights, risk-sharing business model and agile culture to accelerate novel drug development. IAG broadly leverages its core imaging expertise, proprietary technology platform DYNAMIKA and capabilities to support an objective early go no/ go decision and drive excellence for tomorrow’s innovative therapeutic agents with speed. www.ia-grp.com